UK Pharma Execs Urged To Be More Outspoken About Brexit ‘Disaster’
Executive Summary
Pharmaceutical executives from GSK, Sanofi and the UK generic medicines industry body giving evidence on the likely effects of Brexit on the UK life sciences sector at a recent parliamentary committee hearing were asked why they have not been more outspoken about their concerns.
You may also be interested in...
Get Full Regulatory Alignment Or See Post-Brexit Declines In Trials, Manufacturing, Product Launches, Says UK Committee
Stakeholders that gave evidence to a UK parliamentary inquiry into the impact of Brexit on medicines and medical devices said full regulatory alignment was vital if the UK was to avoid declines in clinical trial and manufacturing activity and delays in the launch of new drugs.
GSK Adds £50m Per Year To Brexit Cost Estimates
Brexit is likely to cost GSK around £50m a year in the form of customs duties and transaction and administration costs. It is one of a handful of companies to have made its cost estimates public.
Agree A Brexit Transition By March Or See Pharma Waste Money On Contingency Plans, Says UK Cttee
UK health secretary Jeremy Hunt has been told by the Commons health committee that the government must agree a Brexit transition period that preserves the “regulatory status quo,” otherwise companies will be forced to start spending money on contingency planning that may prove unnecessary.